Why Neubase Therapeutics (NBSE) Shares Are Nosediving

Neubase Therapeutics Inc NBSE shares are trading lower by 53% to $0.47 during Tuesday’s session after the company on Monday announced it is holding a Special Meeting of Stockholders on May 13, online, to discuss and vote on the proposed liquidation and dissolution of the company, along with an adjournment proposal if necessary.

The Board of Directors unanimously recommends voting in favor of these proposals, considering them beneficial for NeuBase and its stockholders. The meeting will be conducted virtually, and stockholders must register by May 12, to attend.

It’s emphasized that both attending and voting are important, and detailed instructions on how to participate and vote are provided in the accompanying proxy statement. The notice is signed by Todd Branning, Interim Chief Executive Officer and Chief Financial Officer.

See Also: Is Donald Trump’s Truth Social’s Public Debut Worth The Hype? Expert Urges Caution

Is NBSE A Good Stock To Buy?

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like NeuBase Therapeutics‘s page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

These are known as capital allocation programs. NeuBase Therapeutics does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

For example, if you're looking to earn an annualized return of 14.97%, you'll need to buy a share of ARMOUR Residential REIT by the Apr. 12, 2024. Once done, you can expect to receive a nominal payout of $0.24 on Apr. 29, 2024.

Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on NeuBase Therapeutics will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

According to data from Benzinga Pro, NBSE has a 52-week high of $5.40 and a 52-week low of $0.59.